Apr 24 |
Immutep reports promising efti/Keytruda data for head and neck cancer
|
Apr 24 |
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
|
Apr 24 |
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
|
Apr 18 |
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
|
Apr 17 |
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
Mar 27 |
Immutep Limited (ASX:IMM): Is Breakeven Near?
|
Mar 24 |
11 Best ASX Stocks To Buy Now
|
Mar 5 |
Immutep Announces First Clinical Data from 90mg Dosing of Efti
|
Feb 29 |
Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%
|
Feb 5 |
10 Best Australian Stocks To Buy
|